Log in to search using one of your social media accounts:

 

Selective PDE4D inhibitor shows potential to treat Fragile X autism spectrum disorder
(Kureczka/Martin Associates) New research suggests the potential utility of BPN14770, a selective PDE4D inhibitor, in the treatment of Fragile X syndrome (FXS) and possibly other autism spectrum disorders. Daily BPN14770 dosing in a mouse Fragile X model showed reduce hyperarousal, improved social interactions and natural behaviors, as well as changes in neuronal dendrite structure. BPM14770 is currently in clinical testing by Tetra Discovery Partners as a prospective treatment for memory and cognitive problems associated with Alzheimer's disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2017 Category: International Medicine & Public Health Source Type: news

Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and autism spectrum disorder. FXS is caused by silencing of the FMR1 gene, which encodes fragile X mental retardation protein (FMRP), an mRNA-binding protein that represses the translation of its target mRNAs. One mechanism by which FMRP represses translation is through its association with cytoplasmic FMRP-interacting protein 1 (CYFIP1), which subsequently sequesters and inhibits eukaryotic initiation factor 4E (eIF4E). CYFIP1 shuttles between the FMRP-eIF4E complex and the Rac1–Wave regulatory complex, thereby connecting translati...
Source: Signal Transduction Knowledge Environment - November 7, 2017 Category: Science Authors: Santini, E., Huynh, T. N., Longo, F., Koo, S. Y., Mojica, E., DAndrea, L., Bagni, C., Klann, E. Tags: STKE Research Articles Source Type: news

Aberrant Rac1-cofilin signaling mediates defects in dendritic spines, synaptic function, and sensory perception in fragile X syndrome
Fragile X syndrome (FXS) is the most common inherited cause of intellectual disabilities and a leading cause of autism. FXS is caused by a trinucleotide expansion in the gene FMR1 on the X chromosome. The neuroanatomical hallmark of FXS is an overabundance of immature dendritic spines, a factor thought to underlie synaptic dysfunction and impaired cognition. We showed that aberrantly increased activity of the Rho GTPase Rac1 inhibited the actin-depolymerizing factor cofilin, a major determinant of dendritic spine structure, and caused disease-associated spine abnormalities in the somatosensory cortex of FXS model mice. Inc...
Source: Signal Transduction Knowledge Environment - November 7, 2017 Category: Science Authors: Pyronneau, A., He, Q., Hwang, J.-Y., Porch, M., Contractor, A., Zukin, R. S. Tags: STKE Research Articles Source Type: news

Neuronal activity drives FMRP- and HSPG-dependent matrix metalloproteinase function required for rapid synaptogenesis
Matrix metalloproteinase (MMP) functions modulate synapse formation and activity-dependent plasticity. Aberrant MMP activity is implicated in fragile X syndrome (FXS), a disease caused by the loss of the RNA-binding protein FMRP and characterized by neurological dysfunction and intellectual disability. Gene expression studies in Drosophila suggest that Mmps cooperate with the heparan sulfate proteoglycan (HSPG) glypican co-receptor Dally-like protein (Dlp) to restrict trans-synaptic Wnt signaling and that synaptogenic defects in the fly model of FXS are alleviated by either inhibition of Mmp or genetic reduction of Dlp. We...
Source: Signal Transduction Knowledge Environment - November 7, 2017 Category: Science Authors: Dear, M. L., Shilts, J., Broadie, K. Tags: STKE Research Articles Source Type: news

Special issue: Fragile X syndrome
In this issue of Science Signaling, three papers uncover molecular mechanisms of neurological dysfunction in animal models of fragile X syndrome. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - November 7, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Positive Topline Results for Cannabinoid Gel in Fragile X Positive Topline Results for Cannabinoid Gel in Fragile X
An investigational transdermal cannabinoid gel led to significant and clinically meaningful improvement in anxiety and difficult behaviors in a phase 2 study of children with fragile X syndrome.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 29, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Why Zynerba's stock soared 62% this week
Zynerba's stock price closed up 62 percent Thursday, at $9.44 per share, after the specialty pharmaceutical company posted positive study results from a midstage clinical trial of its experimental treatment for a rare developmental disorder. The Devon company is attempting to develop synthetic cannabinoid-based therapies for a variety of disorders. Zynerba said in a study of its ZYN002 cannabidiol gel in pediatric and adolescent patients with Fragile X syndrome that the new drug candidates met… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 29, 2017 Category: American Health Authors: John George Source Type: news

Zynerba's stock on a high as cannabis-based drug succeeds in trial
(Reuters) - Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel met the main goal in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities in adolescents and children. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Zynerba's cannabis-based gel meets main goal in mid-stage study
(Reuters) - Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel achieved the main goal in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Zynerba's cannabis-based gel succeeds in mid-stage study
(Reuters) - Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel succeeded in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

New role for fragile X protein could offer clues for treatment
(Howard Hughes Medical Institute) The protein behind fragile X syndrome, a leading cause of autism and intellectual disability, controls a suite of genetic regulators. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 28, 2017 Category: International Medicine & Public Health Source Type: news

New research on Fragile X syndrome reinforces importance of early detection
(Vanderbilt University) New insights into the long-lasting effects of Fragile X syndrome on connections in the brain during early development highlight the importance of early detection and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 25, 2017 Category: International Medicine & Public Health Source Type: news

Children with fragile X syndrome have a bias toward threatening emotion
(Elsevier) Anxiety occurs at high rates in children with fragile X syndrome (FXS), the most common form of inherited intellectual disability. Children with co-occurring anxiety tend to fare worse, but it can be hard to identify in infants. A new study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging reports that infants and children with FXS show bias toward threatening emotion, rather than positive emotion, a pattern highly linked with anxiety. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - August 23, 2017 Category: International Medicine & Public Health Source Type: news

Insight into learning via 'friend of fragile X' gene
(Emory Health Sciences) Fragile X syndrome, caused by a disruption of the gene FMR1, is the most common inherited form of intellectual disability. Emory scientists have revealed new aspects of the function of FMR1 and a 'friend' -- called ZC3H14 in humans/mice and dNab2 in flies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2017 Category: International Medicine & Public Health Source Type: news

A therapy for FXS?
The antidiabetic drug metformin might be repurposed to treat patients with fragile X syndrome. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - July 4, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

UCLA Medical Center doctor under investigation in organ harvesting case
(Natural News) Little Cole Hartman was dealt a bad hand right from the beginning. Born with fragile X syndrome, he had both physical and mental disabilities. When his mom died while he was just a toddler, he was adopted by Jeremy Hartman and his wife Elizabeth. Then, when he was just 8 years old, his... (Source: NaturalNews.com)
Source: NaturalNews.com - June 15, 2017 Category: Consumer Health News Source Type: news

Mice can ’t ‘tune out’ stimuli, mimicking sensory hypersensitivity in humans
This study ’s other authors are Daniel Cantu, Anubhuti Goel, Shilpa Mantri and William Zeiger, all of UCLA.The study was funded by a Paul and Daisy Soros Fellowship for New Americans and an NIH NINDS F30 Fellowship (NS093719); UCLA Neural Microcircuits training grant (T32-NS058280); a Eugene V. Cota-Robles Fellowship; the UCLA Medical Scientist Training Program (NIH NIGMS training grant GM08042; and a Developmental Disabilities Translational Research Program grant (20160969) from the John Merck Fund; a SFARI grant from the Simons Foundation (295438); and NIH NICHD grant (RO1 HD054453). (Source: UCLA Newsroom: Health Sciences)
Source: UCLA Newsroom: Health Sciences - June 12, 2017 Category: Universities & Medical Training Source Type: news

Animal models can't 'tune out' stimuli, mimicking sensory hypersensitivity in humans
(University of California - Los Angeles) Mice genetically engineered to mimic a type of autism in humans, fragile X syndrome, are unable to adapt to, or tune out, repeated stimulation to their whiskers -- unlike ordinary mice. The findings have implications for a common symptom -- sensory hypersensitivity -- in humans with autism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2017 Category: International Medicine & Public Health Source Type: news

Better outcome measures needed for clinical trials for Fragile X Syndrome
(Johns Hopkins Medicine) A group of researchers from several institutions in the USA, including Johns Hopkins Medicine, reports that its review of 22 clinical trials of fragile X syndrome (FXS) suggests the need for a wider use of newer and improved treatment outcome measurement tools for this and other several neurodevelopmental disorders. FXS is the most common inherited form of intellectual disability and the most common form of autism associated with a single gene mutation. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 12, 2017 Category: International Medicine & Public Health Source Type: news

Diabetes drug may help symptoms of autism-associated condition
Metformin, the most widely used drug to treat type 2 diabetes, could potentially be used to treat symptoms of Fragile X syndrome, an inherited form of intellectual disability and a cause of some forms of autism. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 15, 2017 Category: Science Source Type: news

Medical News Today: Metformin shows promise as a potential treatment for fragile X syndrome
New study shows that treatment with the common type 2 diabetes drug metformin improves social, behavioral, and neuron deficits in mouse model of fragile X. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 15, 2017 Category: Consumer Health News Tags: Autism Source Type: news

Diabetes drug may help symptoms of autism-associated condition
Metformin, the most widely used drug to treat type 2 diabetes, could potentially be used to treat symptoms of Fragile X syndrome, an inherited form of intellectual disability and a cause of some forms of autism. A new study led by researchers at McGill University, the University of Edinburgh and Université de Montréal has found that metformin improves social, behavioural and morphological defects in Fragile X mice. (Source: World Pharma News)
Source: World Pharma News - May 15, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Diabetes drug may help symptoms of autism associated condition
(University of Edinburgh) A widely used diabetes medication could help people with a common inherited form of autism, research shows. Scientists found that a drug called metformin improves sociability and reduces symptomatic behaviors in adult mice with a form of Fragile X syndrome. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 15, 2017 Category: International Medicine & Public Health Source Type: news

How Fragile X syndrome disrupts perception
A new study sheds light on the neural mechanisms of Fragile X syndrome. This genetic disorder, which affects males twice as often as females due to males'single X chromosome, causes disruptions in the way neurons transmit information to each other. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2017 Category: Science Source Type: news

Scientists gain insights into how Fragile X syndrome disrupts perception
(VIB (the Flanders Institute for Biotechnology)) A collaboration between scientists in Belgium, the United States, Norway, France and the UK has resulted in a study that sheds light on the neural mechanisms of Fragile X syndrome. This genetic disorder, which affects males twice as often as females due to males' single X chromosome, causes disruptions in the way neurons transmit information to each other. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2017 Category: Global & Universal Source Type: news

Finding drugs for fragile X syndrome
(Source: ScienceNOW)
Source: ScienceNOW - May 4, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: twis Source Type: news

New connections: Treating fragile X syndrome
An in vivo drug screen can identify inhibitors of the signaling pathway that is activated in fragile X syndrome. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - May 2, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Hyperactive locomotion in a Drosophila model is a functional readout for the synaptic abnormalities underlying fragile X syndrome
We report that larval locomotion is augmented in a Drosophila FXS model. Genetic or pharmacological intervention on the BMPR2-LIMK pathway ameliorated the synaptic abnormality and locomotion phenotypes of FXS larvae, as well as hyperactivity in an FXS mouse model. Our study demonstrates that (i) the BMPR2-LIMK pathway is a promising therapeutic target for FXS and (ii) the locomotion phenotype of FXS larvae is a quantitative functional readout for the neuromorphological phenotype associated with FXS and is amenable to the screening novel FXS therapeutics. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - May 2, 2017 Category: Science Authors: Kashima, R., Redmond, P. L., Ghatpande, P., Roy, S., Kornberg, T. B., Hanke, T., Knapp, S., Lagna, G., Hata, A. Tags: STKE Research Resources Source Type: news

Ovid commences Phase I trial of OV101 to treat Angelman / Fragile X syndromes
Biopharmaceutical firm Ovid Therapeutics has commenced the Phase I clinical trial of OV101 for the treatment of adolescents with Angelman syndrome or Fragile X syndrome. (Source: Drug Development Technology)
Source: Drug Development Technology - April 10, 2017 Category: Pharmaceuticals Source Type: news

[Editors' Choice] Impaired phagocytosis in Fragile X
Defects in phagocytosis underlie both neurological and immunological symptoms in a fly model of Fragile X syndrome. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - April 4, 2017 Category: Science Authors: Nancy Gough (mailto:ngough at aaas.org) Source Type: news

Vencerx Therapeutics Announces Appointments of Robert H. Ring, Ph.D. as Chief Executive Officer and Jeffrey Stevenson as Chairman of the Board
NEW YORK, March 31, 2017 -- (Healthcare Sales & Marketing Network) -- Vencerx Therapeutics, a company focused on advancing treatments for neurodevelopmental disorders, today announced the appointments of Robert H. Ring, Ph.D. as Chief Executive Officer an... Biopharmaceuticals, Personnel Vencerx Therapeutics, Fragile X Syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 31, 2017 Category: Pharmaceuticals Source Type: news

Unique Characteristics of the X Chromosome and Related Disorders
This article reviews these unique characteristics and applies their guiding principles in a broad overview to Klinefelter syndrome, ornithine transcarbamylase (OTC) deficiency, hemophilia, and fragile X syndrome. (Source: NeoReviews recent issues)
Source: NeoReviews recent issues - March 31, 2017 Category: Pediatrics Authors: Shah, K., DeRemigis, A., Hageman, J. R., Sriram, S., Waggoner, D. Tags: Pediatric Drug Labeling Update Articles Source Type: news

Take The Autism Challenge
Like many people with autism, my son Danny enjoys Pixar movies and he likes seeing them over and over. Recently, one exchange from the original Toy Story movie started going through my mind. Buzz: Sheriff, this is no time to panic. Woody: This is the perfect time to panic! For me, it’s the perfect time to panic, because Danny turns 21 next week and this is his last year of school. Since he was diagnosed with autism at the age of three, I hoped that he would be able to live and work independently when he grew up. I fought for him to be in mainstream classrooms with a shadow teacher when he was younger. And Danny...
Source: Healthy Living - The Huffington Post - March 30, 2017 Category: Consumer Health News Source Type: news

Treatment window for fragile x likely doesn't close after childhood
(Drexel University) A Drexel University-led study looked into human and rat brain samples and found that the biological structures potentially contributing to Fragile X syndrome are present in adult brains -- something that mouse samples did not show. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2017 Category: Global & Universal Source Type: news

Promising lead reduces autism symptoms and more
Fragile X syndrome is the most common cause of autism. A team of researchers, however, has provided a promising lead in battling this disease. The scientists identified a single protein that appears to be the culprit in causing many behavioral symptoms as well as molecular and cellular abnormalities related to Fragile X. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 8, 2017 Category: Science Source Type: news

Researchers find promising lead that reduces autism symptoms and more
(Michigan State University) Fragile X syndrome is the most common cause of autism. A team of researchers led by Michigan State University, however, has provided a promising lead in battling this disease. In the current issue of Nature Communications, the scientists identified a single protein that appears to be the culprit in causing many behavioral symptoms as well as molecular and cellular abnormalities related to Fragile X. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 8, 2017 Category: Global & Universal Source Type: news

Parenting significantly impacts development of children with Fragile X Syndrome
A longitudinal study of children with Fragile X Syndrome, the leading genetic cause of autism, and their mothers found that sustained maternal responsivity had a significant positive impact on the children's development, even mitigating declines often reported in middle childhood. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 14, 2017 Category: Science Source Type: news

Early brain changes in fragile X syndrome, study shows
A new study is giving researchers a first look at the early stages of brain development in patients with Fragile X syndrome, a disorder that causes mild to severe intellectual disability and is the most common genetic cause of autism spectrum disorder. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 31, 2017 Category: Science Source Type: news

Cannabis Drug Company Zynerba Is Gearing Up For A Big Summer
Zynerba is targeting adult epilepsy, arthritis and Fragile X Syndrome with its synthetic cannabis drugs. Next milestones are expected this summer and equity analysts are on board. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 26, 2017 Category: Pharmaceuticals Authors: Debra Borchardt, Contributor Tags: NASDAQ:ZYNE NASDAQ:GWPH Source Type: news

N.C. babies to get free testing for potentially fatal condition
As early as next year, thousands of North Carolina infants could be tested for symptoms of conditions that could lead to death or disability. The National Center for Advancing Translational Sciences at the National Institutes of Health has awarded funding to a program that will provide free elective genetic testing for spinal muscular atrophy as well as fragile X syndrome in North Carolina infants. Spinal muscular atrophy “is the No. 1 genetic cause of death for infants,” according to nonprofit… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 26, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

Annette Karmiloff-Smith obituary
Neuroscientist who provided fresh insights into our development as individualsWhat is the origin of the unique and complex behaviours that our species are capable of? Is it nature or nurture? How is human cognition – our memory, language, numerical abilities – organised? How do developmental disorders occur? These age-old questions have puzzled – and deeply divided – scientists for hundreds of years. Over the course of more than four decades, research by the developmental neuroscientistAnnette Karmiloff-Smith, who has died aged 78, provided key insights that challenged the traditional answers, and l...
Source: Guardian Unlimited Science - January 26, 2017 Category: Science Authors: Jeffrey Elman and Lorraine Tyler Tags: Neuroscience Psychology Genetics Biology Down's syndrome Health Society Alzheimer's UK news Source Type: news

Main Line biopharm firm gets a boost from the FDA
The Food and Drug Administration has granted Orphan Drug Designation to an experimental therapy Marinus Pharmaceuticals is developing to treat Fragile X Syndrome. That prompts two questions: What is Fragile X Syndrome, and how is the Radnor, Pennsylvania, biopharmaceutical company’s new drug candidate attempting to treat the disorder. Fragile X syndrome is genetic condition that causes a range of developmental problems and symptoms, including cognitive i mpairment, learning disabilities and behavioral… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 3, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
RADNOR, Pa., Jan. 03, 2017 -- (Healthcare Sales & Marketing Network) -- Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announ... Biopharmaceuticals, Neurology, FDA Marinus Pharmaceuticals, ganaxolone, Fragile X Syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 3, 2017 Category: Pharmaceuticals Source Type: news

Neural stem cells serve as RNA highways too
Scientists have caught the first glimpse of molecules shuttling along a sort of highway running the length of neural stem cells, which are crucial to the development of new neurons. This new view has given them an intriguing clue that a protein deficient in Fragile X syndrome, an autism-related disorder that causes intellectual disability, is responsible for moving at least some of this molecular cargo up and down the stem cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 1, 2016 Category: Science Source Type: news

Making Sense of Sensory Processing Disorder
Our bodies are wired for sensory input. Touch, (which includes temperature, texture and pressure), taste, sound, sight and smell are the ways in which we explore the world, from the moment we enter it. When all systems are functioning, we experience a feedback loop. For example, if you were shivering from the cold and wanted to feel warmth, you might put on a cozy sweater or wrap a fleece blanket around your shoulders. Your body would likely respond by relaxing, followed by an emotional relief and perhaps even a sigh. The next time you felt chilly, you would remember what it took to remedy that sensation and follow th...
Source: Psych Central - November 22, 2016 Category: Psychiatry Authors: Edie Weinstein, MSW, LSW Tags: Attention Deficit Disorder Autism / Asperger's Caregivers Children and Teens Genetics Parenting Asperger Syndrome Pervasive Developmental Disorder Sensory integration dysfunction Sensory Processing Disorder Source Type: news

Study implicates glial cells in fragile X syndrome
(University of California - Santa Cruz) Research on fragile X syndrome, the most common inherited cause of mental retardation, has focused mostly on how the genetic defect alters the functioning of neurons in the brain. A new study focusing on a different type of brain cell, the glial cells known as astrocytes, indicates they also are impaired by the genetic defect and are involved in the symptoms of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 4, 2016 Category: Global & Universal Source Type: news

New explanation offered for symptoms of fragile X syndrome
Until recently, scientists thought they understood one of the underlying causes of fragile X syndrome, the most common inherited cause of intellectual disability in the United States. The syndrome, which is associated with autism, was believed to be linked primarily to overactivity in a molecular pathway in the brain. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 21, 2016 Category: Science Source Type: news

New explanation offered for symptoms of fragile X syndrome
A new explanation for some of the symptoms of fragile X syndrome, the most common inherited cause of intellectual disability, has been proposed by researchers. Their explanation suggests new targets for treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 20, 2016 Category: Science Source Type: news

Sertraline, brand named Zoloft, improves functioning in young children with fragile X
Treatment with sertraline may provide nominal but important improvements in cognition and social participation in very young children with fragile X syndrome, the most common genetic cause of intellectual disability and the leading single-gene cause of autism, a study has found. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 26, 2016 Category: Science Source Type: news

Simple, sensitive, and cost-effective assays for analyzing Fragile X-related disorders
Fragile X syndrome, the most common heritable cause of intellectual disability and a frequent cause of autism, is characterized by abnormalities of the FMR1 gene that are difficult to analyze. Preclinical studies of Fragile X and the Fragile X-related disorders are hampered by the lack of low-cost and sensitive yet simple methods. Researchers have now developed a set of assays that are robust, cheap enough for routine research use, and may be suitable for initial patient screening. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 12, 2016 Category: Science Source Type: news